FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4317624038> ?p ?o ?g. }

• W4317624038 endingPage "853" @default.
• W4317624038 startingPage "852" @default.
• W4317624038 abstract "Atrial fibrillation (AF) is the one of the most common arrhythmias seen clinically, with an estimated prevalence of more than 33 million cases worldwide.1Chugh SS Havmoeller R Narayanan K et al.Worldwide epidemiology of atrial fibrillation: A Global Burden of Disease 2010 Study.Circulation. 2014; 129: 837-847Crossref PubMed Scopus (3003) Google Scholar In a vulnerable atrial substrate, a rapid triggering event is able to initiate reentrant waves that lead to the formation of atrial fibrillation.2Iwasaki YK Nishida K Kato T Nattel S. Atrial fibrillation pathophysiology: Implications for management.Circulation. 2011; 124: 2264-2274Crossref PubMed Scopus (554) Google Scholar As time is spent in atrial fibrillation, atrial remodeling can lead to paroxysmal episodes that increase in frequency and duration, causing progression to more persistent AF subtypes, which are not only associated with a decrease in quality of life, but also may be more resistant to treatment; this leads to the saying “AF begets AF.”3Wijffels MC Kirchhof CJ Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats.Circulation. 1995; 92: 1954-1968Crossref PubMed Scopus (2945) Google Scholar,4Dudink EAMP Erküner Ö Berg J et al.The influence of progression of atrial fibrillation on quality of life: A report from the Euro Heart Survey.Europace. 2018; 20: 929-934Crossref PubMed Scopus (24) Google Scholar,5de Vos CB Pisters R Nieuwlaat R et al.Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis.J Am Coll Cardiol. 2010; 55: 725-731Crossref PubMed Scopus (482) Google Scholar Studies have shown that early rhythm control therapy is associated with a lower risk of adverse cardiovascular outcomes.6Kirchhof P Camm AJ Goette A et al.Early rhythm-control therapy in patients with atrial fibrillation.N Engl J Med. 2020; 383: 1305-1316Crossref PubMed Scopus (711) Google Scholar Given the procedural risks of catheter ablation and studies showing that catheter ablation, compared with medical therapy, does not significantly reduce the primary composite endpoint of death, disabling stroke, serious bleeding, or cardiac arrest, current guidelines recommend the use of antiarrhythmic medications as initial therapy for maintenance of sinus rhythm in symptomatic patients.7Packer DL Mark DB Robb RA et al.Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: The CABANA randomized clinical trial.JAMA. 2019; 321: 1261-1274Crossref PubMed Scopus (745) Google Scholar,8Hindricks G Potpara T Dagres N et al.2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC.Eur Heart J. 2021; 42: 373-498Crossref PubMed Scopus (3688) Google Scholar,9January CT Wann LS Calkins H et al.2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A report of the american college of cardiology/american heart association task force on clinical practice guidelines and the heart rhythm society.J Am Coll Cardiol. 2019; 74: 104-132Crossref PubMed Scopus (1124) Google Scholar In November 2022, the New England Journal of Medicine published the results of a 3-year follow-up conducted by Andrade et al. to the Early Aggressive Invasive Intervention for Atrial Fibrillation (EARLY AF) trial.10Andrade JG Deyell MW Macle L et al.Progression of atrial fibrillation after cryoablation or drug therapy.N Engl J Med. 2023; 388: 105-116Crossref PubMed Scopus (27) Google Scholar The EARLY AF trial was a multicenter, randomized trial with blinded endpoint adjudication, comparing the use of cryoballoon ablation to the use of antiarrhythmic drugs in the prevention of atrial fibrillation/tachycardia recurrence using continuous cardiac monitoring over the trial period. The trial was based out of 18 centers in Canada between January 2017 and December 2018, and enrolled 303 patients, with 154 randomly assigned to receive catheter ablation, and the remaining 149 patients received antiarrhythmic therapy. On initial report at one year, the primary endpoint was time to the first documented recurrence of any atrial tachyarrhythmia (atrial flutter/fibrillation/atrial tachycardia) after initiation of antiarrhythmic medication; or 91-to-365 days after catheter ablation (0-90 days is considered a blanking period, in which expert consensus from 2017 stated that any atrial tachyarrhythmias during this period are not to be considered for first clinical failure of the primary endpoint). At the end of the initial report, there was a significantly lower rate of atrial fibrillation recurrence with catheter cryoballoon ablation than with antiarrhythmic drug therapy.11Andrade JG Wells GA Deyell MW et al.Cryoablation or drug therapy for initial treatment of atrial fibrillation.N Engl J Med. 2021; 384: 305-315Crossref PubMed Scopus (267) Google Scholar In this current analysis at 3 years posttreatment, the primary endpoint was time to first occurrence of persistent atrial fibrillation (which was defined as an episode of continuous atrial tachyarrhythmia lasting ≥7 days, or lasting 46 hours-to-7 days but requiring cardioversion for termination). Over the 3-year period, 63 patients who were initially assigned to the antiarrhythmic medication arm underwent catheter ablation after documented arrhythmia recurrence, and 27 patients assigned to cryoballoon ablation. At the end of 3 years, initial treatment of paroxysmal atrial fibrillation with catheter cryoballoon ablation was associated with a lower incidence of persistent atrial fibrillation (hazard ratio 0.25; 95% CI 0.09-0.70) and recurrent atrial tachyarrhythmia than initial use of antiarrhythmic drugs (hazard ratio 0.51; 95% CI 0.38-0.67). Cryoballoon ablation also was associated with lower AF burden (time spent in AF) when compared to use of antiarrhythmic medications. Andrade et al. recognized this trial was performed with cryoballoon ablation, and that the outcomes may not be generalizable to other ablation techniques. However, if the reduction in time to AF and AF burden is essential for slowing down the progression of AF and cardiac remodelling, the use of radiofrequency ablation may be of benefit as well. Previous studies have shown that to there was no/minimal difference in time to first recurrence or AF burden.12Kuck KH Brugada J Fürnkranz A et al.Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation.N Engl J Med. 2016; 374: 2235-2245Crossref PubMed Scopus (1135) Google Scholar,13Hoffmann E Straube F Wegscheider K et al.Outcomes of cryoballoon or radiofrequency ablation in symptomatic paroxysmal or persistent atrial fibrillation.Europace. 2019; 21: 1313-1324Crossref PubMed Scopus (58) Google Scholar,14Chen YH Lu ZY Xiang Y et al.Cryoablation vs. radiofrequency ablation for treatment of paroxysmal atrial fibrillation: A systematic review and meta-analysis.Europace. 2017; 19: 784-794Crossref PubMed Scopus (44) Google Scholar,15Andrade JG Champagne J Dubuc M et al.Cryoballoon or radiofrequency ablation for atrial fibrillation assessed by continuous monitoring: A randomized clinical trial.Circulation. 2019; 140: 1779-1788Crossref PubMed Scopus (277) Google Scholar In regard to catheter ablation therapy versus antiarrhythmic medication therapy, previous studies compared ablation therapy in patients in whom drug therapy already had failed, giving an edge to ablation therapy. Early intervention in patients with AF offers additional potential benefits besides the ones listed above. One benefit is the reduction in needing additional interventions to lower burden of arrythmia. It has been shown that patients with long-standing AF require repeat ablations to decrease the burden of arrythmias.18McCarthy PM Cox JL Kislitsina ON et al.Surgery and catheter ablation for atrial fibrillation: History, current practice, and future directions.J Clin Med. 2022; 11: 210Crossref Scopus (8) Google Scholar Additionally, repeat ablation is a predictor of complications of AF ablation.19Szegedi N Széplaki G Herczeg S et al.Repeat procedure is a new independent predictor of complications of atrial fibrillation ablation.Europace. 2019; 21: 732-737Crossref PubMed Scopus (21) Google Scholar There are several potential areas for future studies. A longer-term follow-up of patients in the EARLY AF trial could further show how early ablation can keep patients out of AF, as opposed to ablation being performed using current guidelines. The EARLY AF study patients had few coexisting conditions and were at low risk for progression of AF.10Andrade JG Deyell MW Macle L et al.Progression of atrial fibrillation after cryoablation or drug therapy.N Engl J Med. 2023; 388: 105-116Crossref PubMed Scopus (27) Google Scholar A potential study could be early catheter ablation against current ablation guidelines in patients with multiple comorbidities. Another potential future study can be to compare the need for additional ablation in patients who have catheter ablation as initial therapy versus the current guidelines. As perioperative physicians, we should be aware that patients with AF are at an increased risk of adverse effects when they present within the perioperative setting. Preoperative AF has been shown to be associated with increases in postoperative adverse effects in patients undergoing noncardiac surgery.20Prasada S Desai MY Saad M et al.Preoperative atrial fibrillation and cardiovascular outcomes after noncardiac surgery.J Am Coll Cardiol. 2022; 79: 2471-2485Crossref PubMed Scopus (3) Google Scholar Prasada et al. found that preexisting AF was associated independently with heart-failure hospitalization, postoperative motility, and stroke within 30 days of noncardiac surgery.20Prasada S Desai MY Saad M et al.Preoperative atrial fibrillation and cardiovascular outcomes after noncardiac surgery.J Am Coll Cardiol. 2022; 79: 2471-2485Crossref PubMed Scopus (3) Google Scholar These outcomes not only increase the burden on patients' quality of life, but also increase healthcare expenditures, especially as the prevalence of AF is projected to increase by 3-fold by 2050.21Morin DP Bernard ML Madias C et al.The state of the art: Atrial fibrillation epidemiology, prevention, and treatment.Mayo Clin Proc. 2016; 91: 1778-1810Abstract Full Text Full Text PDF PubMed Scopus (112) Google Scholar As early catheter ablation prevents AF disease progression and maintenance of sinus rhythm, it could help decrease the perioperative risks that the patients have. Although the current guidelines recommend medical therapy as the initial strategy for rhythm control, this shows the potential benefits of early catheter ablation as an alternative. It is time to consider catheter ablation as a first-line therapy for AF. There have been 2 other multicenter randomized studies, Cryo-FIRST and STOP AF FIRST, that compared cryoablation to antiarrhythmic drugs as first-line therapy, and they both showed similar results to the EARLY AF trial.16Kuniss M Pavlovic N Velagic V et al.Cryoballoon ablation vs. antiarrhythmic drugs: First-line therapy for patients with paroxysmal atrial fibrillation.Europace. 2021; 23: 1033-1041Crossref PubMed Scopus (59) Google Scholar,17Wazni OM Dandamudi G Sood N et al.Cryoballoon ablation as initial therapy for atrial fibrillation.N Engl J Med. 2021; 384: 316-324Crossref PubMed Scopus (225) Google Scholar The results of the trials continue to build the case for catheter ablation as a first-line treatment for AF. None." @default.
• W4317624038 created "2023-01-21" @default.
• W4317624038 creator A5027168830 @default.
• W4317624038 creator A5048854087 @default.
• W4317624038 creator A5090964380 @default.
• W4317624038 date "2023-06-01" @default.
• W4317624038 modified "2023-09-30" @default.
• W4317624038 title "Cryoablation: Sooner or Later?" @default.
• W4317624038 cites W1537095672 @default.
• W4317624038 cites W2017179259 @default.
• W4317624038 cites W2105454146 @default.
• W4317624038 cites W2147018083 @default.
• W4317624038 cites W2333001326 @default.
• W4317624038 cites W2551359113 @default.
• W4317624038 cites W2575627433 @default.
• W4317624038 cites W2629142766 @default.
• W4317624038 cites W2912139642 @default.
• W4317624038 cites W2913088707 @default.
• W4317624038 cites W2920804236 @default.
• W4317624038 cites W2952635553 @default.
• W4317624038 cites W2981584498 @default.
• W4317624038 cites W3082188176 @default.
• W4317624038 cites W3082794714 @default.
• W4317624038 cites W3100870347 @default.
• W4317624038 cites W3101635021 @default.
• W4317624038 cites W3138837606 @default.
• W4317624038 cites W4206574462 @default.
• W4317624038 cites W4283219299 @default.
• W4317624038 cites W4308372963 @default.
• W4317624038 doi "https://doi.org/10.1053/j.jvca.2023.01.016" @default.
• W4317624038 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36925368" @default.
• W4317624038 hasPublicationYear "2023" @default.
• W4317624038 type Work @default.
• W4317624038 citedByCount "0" @default.
• W4317624038 crossrefType "journal-article" @default.
• W4317624038 hasAuthorship W4317624038A5027168830 @default.
• W4317624038 hasAuthorship W4317624038A5048854087 @default.
• W4317624038 hasAuthorship W4317624038A5090964380 @default.
• W4317624038 hasBestOaLocation W43176240381 @default.
• W4317624038 hasConcept C126322002 @default.
• W4317624038 hasConcept C2777628079 @default.
• W4317624038 hasConcept C2778902805 @default.
• W4317624038 hasConcept C71924100 @default.
• W4317624038 hasConceptScore W4317624038C126322002 @default.
• W4317624038 hasConceptScore W4317624038C2777628079 @default.
• W4317624038 hasConceptScore W4317624038C2778902805 @default.
• W4317624038 hasConceptScore W4317624038C71924100 @default.
• W4317624038 hasIssue "6" @default.
• W4317624038 hasLocation W43176240381 @default.
• W4317624038 hasLocation W43176240382 @default.
• W4317624038 hasOpenAccess W4317624038 @default.
• W4317624038 hasPrimaryLocation W43176240381 @default.
• W4317624038 hasRelatedWork W2041017051 @default.
• W4317624038 hasRelatedWork W2379290327 @default.
• W4317624038 hasRelatedWork W2789768125 @default.
• W4317624038 hasRelatedWork W2997066463 @default.
• W4317624038 hasRelatedWork W3209631708 @default.
• W4317624038 hasRelatedWork W4230385422 @default.
• W4317624038 hasRelatedWork W4241018469 @default.
• W4317624038 hasRelatedWork W4244544265 @default.
• W4317624038 hasRelatedWork W4249694486 @default.
• W4317624038 hasRelatedWork W4324131946 @default.
• W4317624038 hasVolume "37" @default.
• W4317624038 isParatext "false" @default.
• W4317624038 isRetracted "false" @default.
• W4317624038 workType "article" @default.